The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of miniDOX (reduced-dose docetaxel/oxaliplatin/capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC): TTD 08-02.
Fernando Rivera
No relevant relationships to disclose
Bartomeu Massuti
No relevant relationships to disclose
Matilde Salcedo
No relevant relationships to disclose
Javier Sastre
No relevant relationships to disclose
Joaquina Martínez-Galán
No relevant relationships to disclose
Manuel Valladares-Ayerbes
No relevant relationships to disclose
Raquel Serrano
No relevant relationships to disclose
Marisa Garcia De Paredes
No relevant relationships to disclose
Josep Tabernero
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech; Merck KGaA; Millennium; Novartis; Onyx
Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi
M. Carmen Galan
No relevant relationships to disclose
Jose Luis Manzano Mozo
No relevant relationships to disclose
Eduardo Diaz Rubio
Consultant or Advisory Role - Roche
Research Funding - Roche
Veronica Conde
No relevant relationships to disclose
Margarita Reboredo
No relevant relationships to disclose
Silvia Vazquez
No relevant relationships to disclose
Laura Layos Romero
No relevant relationships to disclose
Francisco Javier Ramos Pascual
No relevant relationships to disclose
Enrique Aranda
Consultant or Advisory Role - Merck Serono; Roche